Coadministration of lithium and celecoxib reverses manic-like behavior and decreases oxidative stress in a dopaminergic model of mania induced in rats.
Animals
Anti-Inflammatory Agents, Non-Steroidal
/ administration & dosage
Antimanic Agents
/ administration & dosage
Behavior, Animal
/ drug effects
Bipolar Disorder
/ chemically induced
Celecoxib
/ administration & dosage
Dextroamphetamine
/ administration & dosage
Disease Models, Animal
Dopamine
/ metabolism
Drug Therapy, Combination
Frontal Lobe
/ drug effects
Hippocampus
/ drug effects
Lithium Compounds
/ administration & dosage
Male
Motor Activity
/ drug effects
Oxidative Stress
/ drug effects
Rats
Rats, Wistar
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
13 11 2019
13 11 2019
Historique:
received:
04
11
2018
accepted:
20
06
2019
revised:
10
06
2019
entrez:
15
11
2019
pubmed:
15
11
2019
medline:
4
9
2020
Statut:
epublish
Résumé
The present study intends to investigate the effect of lithium (Li) and celecoxib (Cel) coadministration on the behavioral status and oxidative stress parameters in a rat model of mania induced by dextroamphetamine (d-AMPH). Male Wistar rats were treated with d-AMPH or saline (Sal) for 14 days; on the 8th day of treatment, rats received lithium (Li), celecoxib (Cel), Li plus Cel, or water until day 14. Levels of oxidative stress parameters were evaluated in the serum, frontal cortex, and hippocampus. d-AMPH administration induced hyperlocomotion in rats, which was significantly reversed by Li and Cel coadministration. In addition, d-AMPH administration induced damage to proteins and lipids in the frontal cortex and hippocampus of rats. All these impairments were reversed by treatment with Li and/or Cel, in a way dependent on cerebral area and biochemical analysis. Li and Cel coadministration reversed the d-AMPH-induced decrease in catalase activity in cerebral structures. The activity of glutathione peroxidase was decreased in the frontal cortex of animals receiving d-AMPH, and treatment with Li, Cel, or a combination thereof reversed this alteration in this structure. Overall, data indicate hyperlocomotion and alteration in oxidative stress biomarkers in the cerebral structures of rats receiving d-AMPH. Li and Cel coadministration can mitigate these modifications, comprising a potential novel approach for BD therapy.
Identifiants
pubmed: 31723123
doi: 10.1038/s41398-019-0637-9
pii: 10.1038/s41398-019-0637-9
pmc: PMC6853972
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Antimanic Agents
0
Lithium Compounds
0
Celecoxib
JCX84Q7J1L
Dextroamphetamine
TZ47U051FI
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
297Références
J Neurosci. 1999 Feb 15;19(4):1484-91
pubmed: 9952424
J Psychiatr Res. 2010 Oct;44(14):903-9
pubmed: 20334877
J Psychiatr Res. 2007 Sep;41(6):523-9
pubmed: 16956621
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:230-7
pubmed: 23333378
Epilepsy Behav. 2018 Mar;80:144-151
pubmed: 29414544
Biol Psychiatry. 2013 Jul 1;74(1):15-25
pubmed: 23419545
Neuropsychiatr Dis Treat. 2016 Jul 11;12:1687-703
pubmed: 27468233
J Neuroinflammation. 2004 May 17;1(1):6
pubmed: 15285796
Health Expect. 2009 Jun;12(2):120-9
pubmed: 19538647
Braz J Psychiatry. 2011 Mar;33(1):72-80
pubmed: 21537724
Neurochem Int. 2013 Nov;63(5):345-53
pubmed: 23871716
Expert Rev Mol Diagn. 2016 Nov;16(11):1209-1220
pubmed: 27737600
Hum Psychopharmacol. 2008 Mar;23(2):87-94
pubmed: 18172906
Am J Ther. 2001 Mar-Apr;8(2):85-95
pubmed: 11304662
Eur J Pharmacol. 2002 Aug 23;450(2):141-51
pubmed: 12206852
J Clin Psychiatry. 2009 Aug;70(8):1078-90
pubmed: 19497250
J Psychiatry Neurosci. 2009 Jul;34(4):263-71
pubmed: 19568477
Ann N Y Acad Sci. 2010 Feb;1187:101-21
pubmed: 20201848
Discov Med. 2004 Oct;4(23):239-45
pubmed: 20704954
J Child Adolesc Psychopharmacol. 2017 Aug;27(6):494-500
pubmed: 28409660
J Psychiatry Neurosci. 2008 Nov;33(6):516-24
pubmed: 18982174
J Clin Psychiatry. 2003 Nov;64(11):1328-34
pubmed: 14658947
Neuroimmunomodulation. 2014;21(2-3):117-22
pubmed: 24557044
J Affect Disord. 2015 Mar 15;174:467-78
pubmed: 25553408
Pharmacol Biochem Behav. 2019 Aug;183:56-63
pubmed: 31158395
J Neurochem. 2008 Jul;106(2):696-705
pubmed: 18410508
J Psychopharmacol. 2012 Dec;26(12):1594-604
pubmed: 23076832
Metabolism. 2000 Feb;49(2 Suppl 1):3-8
pubmed: 10693912
Biomed Pharmacother. 2016 Aug;82:425-31
pubmed: 27470381
Life Sci. 2016 Oct 15;163:23-37
pubmed: 27580523
Methods Enzymol. 1994;233:346-57
pubmed: 8015469
Cancer Chemother Pharmacol. 2010 Jan;65(2):267-76
pubmed: 19506872
J Psychiatr Res. 1999 Jul-Aug;33(4):335-40
pubmed: 10404471
Am J Psychiatry. 2000 May;157(5):683-94
pubmed: 10784457
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):143-8
pubmed: 22691715
J Neurosci. 2007 Sep 19;27(38):10116-27
pubmed: 17881518
J Affect Disord. 2013 May;147(1-3):325-30
pubmed: 23261141
J Affect Disord. 2019 Feb 15;245:1106-1113
pubmed: 30699853
J Neuroinflammation. 2013 Apr 05;10:45
pubmed: 23561827
Braz J Psychiatry. 2013;35 Suppl 2:S121-31
pubmed: 24271224
J Neural Transm (Vienna). 2012 Jan;119(1):31-8
pubmed: 21858431
Methods Enzymol. 1981;77:325-33
pubmed: 7329310
Mini Rev Med Chem. 2015;15(5):355-65
pubmed: 25807948
J Psychiatry Neurosci. 2006 Sep;31(5):326-32
pubmed: 16951735
Bipolar Disord. 2006 Jun;8(3):275-80
pubmed: 16696830
Nat Neurosci. 2010 Oct;13(10):1161-9
pubmed: 20877280
Bipolar Disord. 2015 Sep;17(6):606-14
pubmed: 26291962
Methods Enzymol. 1990;186:407-21
pubmed: 2233308
Methods Enzymol. 1984;105:121-6
pubmed: 6727660
Bipolar Disord. 2015 Aug;17(5):507-17
pubmed: 25929806
Behav Brain Res. 2012 Oct 1;234(2):285-91
pubmed: 22796600
Ann Pharmacother. 2004 Jul-Aug;38(7-8):1189-93
pubmed: 15187206
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:353-362
pubmed: 29555252
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Aug 4;53:23-34
pubmed: 24468642
J Psychopharmacol. 2018 Nov 29;:269881118812235
pubmed: 30488738
J Psychiatry Neurosci. 2014 May;39(3):189-99
pubmed: 24290077
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jan 4;72:73-86
pubmed: 27616052
Pharmacol Biochem Behav. 2013 Jan;103(3):589-96
pubmed: 23010382
Int J Biomed Sci. 2007 Sep;3(3):176-84
pubmed: 23675041